116 related articles for article (PubMed ID: 14534528)
1. Acute expression of RET/PTC induces isozyme-specific activation and subsequent downregulation of PKCepsilon in PCCL3 thyroid cells.
Knauf JA; Ouyang B; Croyle M; Kimura E; Fagin JA
Oncogene; 2003 Oct; 22(44):6830-8. PubMed ID: 14534528
[TBL] [Abstract][Full Text] [Related]
2. RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response.
Puxeddu E; Knauf JA; Sartor MA; Mitsutake N; Smith EP; Medvedovic M; Tomlinson CR; Moretti S; Fagin JA
Endocr Relat Cancer; 2005 Jun; 12(2):319-34. PubMed ID: 15947106
[TBL] [Abstract][Full Text] [Related]
3. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling.
Mesa C; Mirza M; Mitsutake N; Sartor M; Medvedovic M; Tomlinson C; Knauf JA; Weber GF; Fagin JA
Cancer Res; 2006 Jul; 66(13):6521-9. PubMed ID: 16818623
[TBL] [Abstract][Full Text] [Related]
4. Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells.
Castellone MD; Celetti A; Guarino V; Cirafici AM; Basolo F; Giannini R; Medico E; Kruhoffer M; Orntoft TF; Curcio F; Fusco A; Melillo RM; Santoro M
Oncogene; 2004 Mar; 23(12):2188-96. PubMed ID: 14981541
[TBL] [Abstract][Full Text] [Related]
5. Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas.
Castellone MD; Guarino V; De Falco V; Carlomagno F; Basolo F; Faviana P; Kruhoffer M; Orntoft T; Russell JP; Rothstein JL; Fusco A; Santoro M; Melillo RM
Oncogene; 2004 Aug; 23(35):5958-67. PubMed ID: 15184868
[TBL] [Abstract][Full Text] [Related]
6. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
7. Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels.
Wang J; Knauf JA; Basu S; Puxeddu E; Kuroda H; Santoro M; Fusco A; Fagin JA
Mol Endocrinol; 2003 Jul; 17(7):1425-36. PubMed ID: 12690093
[TBL] [Abstract][Full Text] [Related]
8. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
[TBL] [Abstract][Full Text] [Related]
9. Microsomal prostaglandin E2 synthase-1 is induced by conditional expression of RET/PTC in thyroid PCCL3 cells through the activation of the MEK-ERK pathway.
Puxeddu E; Mitsutake N; Knauf JA; Moretti S; Kim HW; Seta KA; Brockman D; Myatt L; Millhorn DE; Fagin JA
J Biol Chem; 2003 Dec; 278(52):52131-8. PubMed ID: 14555660
[TBL] [Abstract][Full Text] [Related]
10. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
[TBL] [Abstract][Full Text] [Related]
11. Activation of signal transducer and activator of transcription 3 by oncogenic RET/PTC (rearranged in transformation/papillary thyroid carcinoma) tyrosine kinase: roles in specific gene regulation and cellular transformation.
Hwang JH; Kim DW; Suh JM; Kim H; Song JH; Hwang ES; Park KC; Chung HK; Kim JM; Lee TH; Yu DY; Shong M
Mol Endocrinol; 2003 Jun; 17(6):1155-66. PubMed ID: 12637586
[TBL] [Abstract][Full Text] [Related]
12. H4(D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: functional characterization.
Celetti A; Cerrato A; Merolla F; Vitagliano D; Vecchio G; Grieco M
Oncogene; 2004 Jan; 23(1):109-21. PubMed ID: 14712216
[TBL] [Abstract][Full Text] [Related]
13. Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins.
Richardson DS; Gujral TS; Peng S; Asa SL; Mulligan LM
Cancer Res; 2009 Jun; 69(11):4861-9. PubMed ID: 19487296
[TBL] [Abstract][Full Text] [Related]
14. RET oncogene activation in papillary thyroid carcinoma.
Tallini G; Asa SL
Adv Anat Pathol; 2001 Nov; 8(6):345-54. PubMed ID: 11707626
[TBL] [Abstract][Full Text] [Related]
15. RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase.
Knauf JA; Kuroda H; Basu S; Fagin JA
Oncogene; 2003 Jul; 22(28):4406-12. PubMed ID: 12853977
[TBL] [Abstract][Full Text] [Related]
16. XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway.
Lodyga M; De Falco V; Bai XH; Kapus A; Melillo RM; Santoro M; Liu M
Oncogene; 2009 Feb; 28(7):937-49. PubMed ID: 19060924
[TBL] [Abstract][Full Text] [Related]
17. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells.
Mitsutake N; Knauf JA; Mitsutake S; Mesa C; Zhang L; Fagin JA
Cancer Res; 2005 Mar; 65(6):2465-73. PubMed ID: 15781663
[TBL] [Abstract][Full Text] [Related]
18. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids.
Powell DJ; Russell J; Nibu K; Li G; Rhee E; Liao M; Goldstein M; Keane WM; Santoro M; Fusco A; Rothstein JL
Cancer Res; 1998 Dec; 58(23):5523-8. PubMed ID: 9850089
[TBL] [Abstract][Full Text] [Related]
19. Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements.
Mechler C; Bounacer A; Suarez H; Saint Frison M; Magois C; Aillet G; Gaulier A
Br J Cancer; 2001 Dec; 85(12):1831-7. PubMed ID: 11747322
[TBL] [Abstract][Full Text] [Related]
20. BRAFV600E and RET/PTC Promote Proliferation and Migration of Papillary Thyroid Carcinoma Cells In Vitro by Regulating Nuclear Factor-κB.
Zhou D; Li Z; Bai X
Med Sci Monit; 2017 Nov; 23():5321-5329. PubMed ID: 29117154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
